Objective: In recent years, the therapeutic use of Janus kinase (JAK) inhibitors in dermatology, particularly in the management of atopic dermatitis (AD), has expanded markedly. This bibliometric study aimed to characterize research themes, evaluate the scientific productivity of authors and countries, and identify emerging areas that may guide future research in this field over the past decade.
Materials and Methods: A bibliometric analysis of JAK inhibitors in AD from 2015 to 2025 was conducted using the Web of Science Core Collection (WoSCC) database as the data source. Bibliometric analyses and data visualizations were performed using CiteSpace, VOSviewer, and the Bibliometrix package in R.
Results: A total of 1249 studies were included in the analysis. The cluster plot classified all keywords into 9 categories. Pruritus and alopecia areata (AA) were the most frequently co-occurring keywords alongside atopic dermatitis, while delgocitinib and abrocitinib were the most frequently investigated JAK inhibitors. The United States produced the highest number of publications over the past decade. Oregon Health and Science University emerged as one of the most significant contributors to global collaborations, while the Icahn School of Medicine had the highest number of publications, reaching approximately 175 by 2025. Simpson EL emerged as both the most influential and the most cited author in the field, as reflected by citation impact, followed by Emma Guttman-Yassky.
Conclusion: Janus kinase (JAK) inhibitors represent one of the most effective and trending therapeutic classes in AD. These agents are not only highly effective for AD but also show promising efficacy in other dermatologic conditions, such as AA.